An Obvious Escape: Entrepreneurs 1 versus VC Overlords 0

The New York Times has run a piece on Ev Williams and his recent buy out of Odeo from VCs Charles River Ventures. I’m not overly enthused with some of Miguel Helft’s wording – “struggling podcast company”, but on the whole it’s a great snapshot of thinking behind the move by some of us to focus on building multi-product, sustainable companies.

 The best thing about the newly renamed Obvious, Mr. Williams said, is that he controls its destiny. He wants it to become a sort of idea factory that can spawn project after project, perhaps not unlike a media company that starts magazine after magazine. Obvious already has two projects, Odeo, which soldiers on, and Twitter, a blogging-like tool for quick updates.


One response to “An Obvious Escape: Entrepreneurs 1 versus VC Overlords 0

  1. David gigolashvili.

    From: David Gigolashvili.
    General Director.
    Company “777” Ltd.

    Dear, Ladies and Gentlemen!
    Our group – Doctor of pharmaceutical Sciences, professor, academician Vajha Eriashvili, Laureate of state premium, doctor of medical sciences, professor Alexander Tsalughelashvili, engineer and economist David Gigolashvili, – The project for biopharmaceutical research anufacturing, reception of liquid and steady medicinal forms, Biopharmaceuticals, The factory will let out (physiological) intravenous solutions IVPC of transfusion and a syringe, the US FDA (GMP) standards in Georgia. We established “777” LTD company, which is registered in Tbilisi, 24th of December 1998 year, 20643846.

    With that end in view we carry on negotiations with «S.B.T Technologies.»as they can supply us with technologies, project of equipments and systems that meet the GMP&ISO 9002 standards.

    Our Facility’s design is the latest in State-of-the Art manufacturing technology and is built to be more flexible in its production capacities, and to enhance the quality of the environment in which Iv Solutions are produced. Better controlled, cleaner environment, better, safer products!

    Production of IVPC is very actual in Georgia. Technological presses offered by European IVPC producers don’t meet the standards of clean environment (class 100) that is required by US FDA standards. Nowadays IVPC production and realization is possible neither in Georgia nor in European and UIS (Union of Independent States) countries.

    IVPC demand in US and Canada is 4 L. per inhabitant every year, 3,5 L in Europe, in Georgia according to World Organization of Health is needed no less than 1 L. IPVC.

    In this project it is also foreseen preparation of cadres in US according to US FDA (GMP) demands.

    IVPC Facility are designed and built to meet the US FDA (GMP) extremely stringent quality standards, which are acceptable worldwide. Therefore, the product manufactured by our Facility can be marked on a global scale.

    None of the Facilities built by European companies can offer the same.

    As you can see IVPC Facility, no matter what production configuration you choose, offer the highest cost effectiveness (capital outlay per one unit of production capability ratio) and therefore the highest and fastest return on investment.

    In general, it is well known fact that the level of medicine practiced in the United States and medical products used in US are superior to most European countries because of the high standards, strict requirements and stringent regulations the US Government through its FDA imposes on medical industry. All these quality are reflected in the products our industry manufactures and offers.

    We inform that Government consider the realization of project of IVPC advisable and they are ready to help us. According to above-mentioned the building of IVPC producer Facility that meet the GMP standards is very important and they are ready to discuss and carry on negotiations with investors about financing of this project.

    In addition, in parallel on the basis of a factory we plan to create biopharmaceutical research manufacture of reception of liquid and firm medicinal forms.

    Since 1980, in Tbilisi, the Republic of Georgia, has been founded the Research Bipharmacy Centre the main purpose of which is to create pharmaceutical preparations utilizing local raw materials.

    At the Research Biopharmacy Centre, the Republic of Georgia, a completely novel local raw material has been fond to contain up to 30 – 40mg% of Hyaluronic acid, and the molecular weight is fluctuating approximately from to 7 millions.

    The initial hurification and investigation of the material was conducted through sectrophotome try. At the moment, due to the lack of necessary equipment the further purification of our material as its dosage form obtaining and standardization have become impracticable.

    Dear Sir, we would like offer you to undertake the purification and standardization of our specimen for which our semiproduct in the liquid or solid (powder) form will be immediately send to you at you request, if any.

    We consider it expedient cooperate with you and to start joint production of the Hyaluronic acid in Georgia should you be interested.

    Preliminary estimation has shown that about 0,1 kg of Hyaluronic acid and more can be produced in Georgia at the initial stage.

    Dear,Ladies and Gentlemen! We hope that you will discuss our project carefully and positively decide to help us in finding financial source for realization of this project.

    I hope that our collaboration will be fertile and useful.

    Yours respectfully,
    David Gigolashvili
    General Director
    “777” Company


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s